1028266-22-9

Upstream product

• 336119-88-1 (±)-2-(1-amino-2-methylpropyl)-3-benzyl-7-chloroquinazolin-4(3H)-one 
• 587881-25-2 (±)-2-(1-azido-2-methylpropyl)-3-benzyl-7-chloroquinazolin-4(3H)-one 
• 587881-24-1 (±)-3-benzyl-2-(1-bromo-2-methylpropyl)-7-chloroquinazolin-4(3H)-one 
• 587881-23-0 3-benzyl-7-chloro-2-(2-methylpropyl)-3,4-dihydroquinazolin-4-one 
• 587881-22-9 7-chloro-2-isobutyl-4H-benzo[d][1,3]oxazin-4-one 
• 887636-73-9 C₁₂H₁₄ClNO₃ 
• 108-12-3 isopentanoyl chloride 
• 89-77-0 2-Amino-4-chlorobenzoic acid 
• 1417617-03-8 tert-butyl (3-(N-(1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl)-4-fluorobenzamido)propyl)carbamate 
• 1314917-40-2 (±)-tert-butyl (3-((1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl)amino)propyl)carbamate 

Relevant academic research and scientific papers

Fluorinated quinazolinones as potential radiotracers for imaging kinesin spindle protein expression

Anti-mitotic anti-cancer drugs offer a potential platform for developing new radiotracers for imaging proliferation markers associated with the mitosis-phase of the cell-cycle. One interesting target is kinesin spindle protein (KSP) - an ATP-dependent motor protein that plays a vital role in bipolar spindle formation. In this work we synthesised a range of new fluorinated-quinazolinone compounds based on the structure of the clinical candidate KSP inhibitor, ispinesib, and investigated their properties in vitro as potential anti-mitotic agents targeting KSP expression. Anti-proliferation (MTT and BrdU) assays combined with additional studies including fluorescence-assisted cell sorting (FACS) analysis of cell-cycle arrest confirmed the mechanism and potency of these biphenyl compounds in a range of human cancer cell lines. Additional studies using confocal fluorescence microscopy showed that these compounds induce M-phase arrest via monoaster spindle formation. Structural studies revealed that compound 20-(R) is the most potent fluorinated-quinazolinone inhibitor of KSP and represents a suitable lead candidate for further studies on designing 18F-radiolabelled agents for positron-emission tomography (PET).